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Objective: To assess whether plasma IGFBP-2 is independently associated with components of the
lipoprotein-lipid proﬁle and to suggest a cutoff value that could identify subjects with the features of the
metabolic syndrome. Methods: In this cross-sectional study, 379 Caucasian men from the general
population and covering a wide range of BMI were recruited through the media. Subjects with type 2
diabetes, BMI values > 40 kg/m2, or taking medication targeting glucose or lipid metabolism or blood
pressure were excluded. Anthropometric data were collected and plasma IGFBP-2 concentrations,
glucose tolerance and an extensive plasma lipid proﬁle were determined after an overnight fast. Results:
Subjects with low IGFBP-2 levels were characterized by increased fat mass (p < 0.0001), impaired insulin
sensitivity (p < 0.0001) and higher plasma triglyceride (TG) levels (p < 0.0001). When divided into 6
quantiles, only subjects with the highest IGFBP-2 levels (>221.5 ng/mL) did not meet the NCEP ATP III
criteria for the clinical diagnosis of the metabolic syndrome. In addition, circulating IGFBP-2 levels were
signiﬁcantly associated with VLDL-TG (r ¼ 0.51, p < 0.0001) and HDL-C (r ¼ 0.27, p < 0.0001) levels.
After adjustments, plasma IGFBP-2 was found to be independently associated with VLDL-TG levels but
not with HDL-C concentrations. Conclusions: In our cohort, IGFBP-2 levels <221.5 ng/mL are incre-
mentally associated with a detrimental plasma lipoprotein-lipid proﬁle. After adjustment for covariates,
IGFBP-2 remained independently associated with VLDL-TG but not HDL-C levels. This study supports
further investigations in other populations and validation of IGFBP-2 as a biomarker of early
dyslipidemia.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).m the CIHR to F Picard (CCI-
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Dyslipidemia often precedes the appearance of type 2 diabetes
by several years. This indicates that dysfunctions in lipid meta-
bolism are one of the ﬁrst elements leading to cardiovascular
complications in these patients. It is now recognized that the
various components of diabetic dyslipidemia are not isolated ab-
normalities but are metabolically linked to each other and are
partly driven by the hepatic overproduction of large triglyceride
(TG)-rich very low-density lipoproteins (VLDL) [1]. This over-
production seems to trigger changes in intravascular lipoprotein
metabolism that are associated with an increased cardiovasculararticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
S. Carter et al. / Atherosclerosis 237 (2014) 645e651646risk [i.e. smaller low-density lipoprotein (LDL) and decrease in size
and number of high-density lipoprotein (HDL) particles] [2].
Fat accretion in both hepatic and intra-abdominal (or visceral)
adipose tissues has been proposed to be involved in the develop-
ment of dyslipidemia [3,4]. Studies conducted in humans showed
that visceral adipose tissue and liver fat accumulation are both
associated with impaired glucose tolerance, insulin resistance and
increased VLDL secretion [2,5,6]. These metabolic alterations also
inﬂuence the production of adipokines and hepatokines [7]. Pro-
inﬂammatory cytokines such as C-reactive protein (CRP), IL-6 and
tumor necrosis factor (TNF)-a are upregulated in visceral obesity,
which triggers low grade inﬂammation, a hallmark of obesity.
Circulating insulin-like growth factor-binding protein (IGFBP)-2,
can modulate the effects of IGF on metabolism [8] by inﬂuencing
the binding of IGF to IGF receptors [9] and through IGF-
independent effects mediated via integrin signaling [10,11]. In
humans, low IGFBP-2 levels have been associated with conditions
of obesity and insulin resistance [8,12e15]. In addition, global es-
timates of the metabolic syndrome [16] and cardiovascular risk
markers [17] negatively correlate with circulating IGFBP-2 levels. In
line with this concept, IGFBP-2 has been shown to protect against
age- and diet-induced insulin resistance when overexpressed in
rodents using either transgenic [18,19] or adenoviral techniques
[20].
IGFBP-2 has been negatively associated with circulating TG and
cholesterol levels [13,16,17,21]. However, only a limited number of
studies have investigated the impact of IGFBP-2 on lipid meta-
bolism [21]. In order to dissociate the interaction of IGFBP-2 with
lipids beyond its relation with insulin sensitivity and fat mass, the
present study aimed at exploring the associations between circu-
lating levels of IGFBP-2 and several features of the plasma lipo-
protein/lipid proﬁle in a cohort of men covering a large range of
adiposity. Since features of the metabolic syndrome have been
found to be associated with IGFBP-2 levels, this study also aimed at
suggesting a cut-off value of circulating IGFBP-2 that could help
identify subjects with the features of the metabolic syndrome.
2. Materials and methods
2.1. Study design
This cross-sectional study was performed in a sample of 379
asymptomatic Caucasian adult men, between the ages of 20e65
years from the Quebec City metropolitan area. Subjects were
recruited by solicitation in the media and selected to cover a wide
range of body fatness values. Subjects with type 2 diabetes, body
mass index (BMI) values > 40 kg/m2, or takingmedication targeting
glucose or lipid metabolism or blood pressure were excluded.
Informed written consent was obtained from all participants prior
to their inclusion in the study, which was approved by the Medical
Ethics Committees of Universite Laval and the Institut universitaire
de cardiologie et de pneumologie de Quebec.
2.2. Anthropometric measurements and computed tomography
Height, weight, waist circumference and fat mass were
measured according to standardized procedures [22,23]. Abdom-
inal visceral and subcutaneous fat areas were assessed by
computed tomography. Measurements of abdominal adipose tissue
depots were obtained at the L4eL5 intervertebral space with sub-
jects lying in the supine position with both arms stretched above
the head as previously reported [24]. Visceral adipose tissue area
was determined by delineating the middle of the muscle wall
surrounding the abdominal cavity. The subcutaneous adipose tis-
sue corresponded to the amount of fat located from the skin to themiddle of the muscle wall surrounding the abdominal cavity. Adi-
pose tissue areas (cm2) were computed using an attenuation range
of 190 to 30 Hounsﬁeld units as previously described [24].
2.3. Plasma lipoprotein-lipid proﬁle
Blood samples were collected from the antecubital vein after a
12 h overnight fast for the measurement of plasma lipid and lipo-
protein levels. TG and cholesterol levels were determined in plasma
and lipoprotein fractions using Technicon RA-500 (Bayer Corpora-
tion, Tarrytown, NY, USA); enzymatic reagents were obtained from
Randox (Crumlin, UK). TG-rich lipoproteins (VLDL) were ﬁrst
removed by ultracentrifugation [25]. The HDL fraction was ob-
tained after precipitation of the remaining apolipoprotein (apo) B-
containing lipoproteins, primarily LDL, in the infranatant
(density > 1.006 g/mL) with heparin and MnCl2 [26]. Cholesterol
and TG concentrations in the infranatant were measured before
and after the precipitation step, allowing the calculation of LDL-C
levels [27]. Plasma apo B and A1 concentrations were measured
according to standardized procedures [28,29].
2.4. LDL size
The LDL peak particle diameter was obtained from non-
denaturing 2e16% polyacrylamide gradient gel electrophoresis as
previously described [30]. LDL particle size was extrapolated from
the relative migration of four plasma standards of known di-
ameters. The estimate diameter for the major peak in each scanwas
identiﬁed as the LDL peak particle size. The relative proportion of
LDL with a diameter smaller than 255 Å was determined by
computing the relative area of the densitometric scan corre-
sponding to LDL particles smaller than 255 Å. Sudan black staining
was assumed to closely reﬂect the cholesterol distribution among
LDL particles of different sizes [31]. The absolute concentration of
cholesterol among particles smaller than 255 Å was calculated by
multiplying plasma LDL-C levels by the relative proportion of LDL
with a diameter smaller than 255 Å. A similar approach was used to
assess the relative and absolute concentrations of cholesterol in LDL
particles with a diameter greater than 260 Å.
2.5. HDL size
Nondenaturing 4e30% polyacrylamide gel electrophoresis was
performed for the measurement of HDL size as previously
described [32]. The mean HDL particle size represents the overall
distribution of HDL subspecies and was obtained with the migra-
tion of lipid-stainable plasma standards of known diameters [35].
2.6. Oral glucose tolerance test (OGTT)
After a 12 h overnight fast, participants were subjected to a 75 g
oral glucose load. Blood samples were taken at15, 0,15, 30, 45, 60,
90, 120, 150 and 180 min for the measurement of plasma glucose
and insulin concentrations. The total glucose and insulin area under
the curve (AUC) during the OGTTwere determined by the trapezoid
method between 0 and 180 min. The homeostasis model assess-
ment of insulin resistance (HOMA-IR) was calculated from fasting
glucose and insulin values, as previously described [33].
2.7. Determination of cardiometabolic risk markers
Fasting plasma adiponectin, IL-6, TNF-a, alanine transaminase
(ALT), leptin and hs-CRP levels were assessed on deeply frozen
samples (80 C). Adiponectin and leptin concentrations were
quantiﬁed by ELISA (B-Bridge International, Inc. Sunnyvale, CA).
S. Carter et al. / Atherosclerosis 237 (2014) 645e651 647Plasma IL-6 and TNF-a concentrations were measured by high
sensitivity ELISA (R&D Systems Inc., Minneapolis, MN, USA). hs-CRP
levels were measured with a highly sensitive immunoassay using a
monoclonal antibody coated with polystyrene particles; the assay
was performed with a BN ProSpec nephelometer (Dade Behring,
Germany) according to the manufacturer's instructions. Plasma hs-
CRP values >10 mg/L were excluded from the analyses [34]. The
intra- and inter-assay coefﬁcients of variation were <10% and <20%
for all ELISA cytokinemeasurements and<5% for automated hs-CRP
measurements.2.8. IGFBP-2 quantiﬁcation
Plasma IGFBP-2 levels were measured by ELISA (Mediagnost,
Reutlingen, Germany; no cross reactivity with IGFBP-1 nor IGFBP-3)
on samples kept at 80 C and according to the manufacturer'sTable 1
Characteristics of the sample of 379 men.
Variables Total N ¼ 379 Low IGF
Anthropometric data
Age (years) 45.1 ± 9.7 44.6
Weight (kg) 90.6 ± 14.5 96.5
Body mass index (kg/m2) 29.7 ± 4.3 31.7
Waist circumference (cm) 103.3 ± 12.6 108.8
Fat mass (kg) 22.1 ± 9.4 30.3
L4-L5 visceral AT (cm2) 203.1 ± 84.5 236.0
L4-L5 subcutaneous AT (cm2) 287.7 ± 113.4 332.7
Glucose metabolism
Fasting glucose (mmol/L) 5.76 ± 0.49 5.85
AUC glucose (mmol/L  180 min) 1362 ± 250 1448
Fasting insulin (pmol/L)b 126.6 ± 75.6 163.7
AUC insulin (pmol/L  180 min)b 134,142 ± 102060 172,936
HOMA-IRb 4.59 ± 2.9 5.97
Circulating factors
ALT (U/L)b 24.3 ± 13.0 28.0
Leptin (ng/mL)b 11.7 ± 7.89 12.7
C-reactive proteinb (mg/L) 2.17 ± 1.97 2.24
IL-6 (pg/mL)b 1.29 ± 0.95 1.22
Adiponectin (mg/mL)b 6.54 ± 5.48 4.46
TNF-a (pg/mL)b 1.22 ± 1.42 1.07
IGFBP-2 (ng/mL) 158.2 ± 79.4 e
Plasma lipids
Triglycerides (mmol/L)b 2.21 ± 1.09 2.61
Cholesterol (mmol/L) 5.06 ± 0.84 5.21
Cholesterol/HDL cholesterol 5.43 ± 1.29 5.76
Apolipoprotein B (g/L) 1.07 ± 0.21 1.12
Apolipoprotein A1 (g/L) 1.16 ± 0.16 1.15
VLDL
VLDL apo B (g/L) 0.16 ± 0.06 0.18
VLDL triglycerides (mmol/L)b 1.7 ± 0.99 2.04
VLDL cholesterol (mmol/L)b 0.89 ± 0.52 1.05
LDL
LDL apo B (g/L) 0.91 ± 0.19 0.94
LDL triglycerides (mmol/L)b 0.29 ± 0.11 0.32
LDL cholesterol (mmol/L) 3.20 ± 0.76 3.24
Large LDL (mmol/L) 0.88 ± 0.52 0.83
Medium LDL (mmol/L) 0.59 ± 0.27 0.57
Small LDL (mmol/L) 1.71 ± 0.62 1.74
% Large LDL 27.2 ± 13.8 26.0
% Medium LDL 18.2 ± 6.32 17.6
% Small LDL 54.7 ± 18.0 56.5
LDL size (Å) 252.3 ± 4.5 251.9
HDL
HDL triglycerides (mmol/L)b 0.22 ± 0.06 0.24
HDL cholesterol (mmol/L)b 0.97 ± 0.21 0.93
HDL size (Å) 81.9 ± 2.3 81.7
Apo: Apolipoprotein, AT: Adipose tissue, ALT: Alanine transaminase, AUC: Area under the
insulin resistance, IGFBP: Insulin-like growth factor binding protein, LDL: Low-density lip
mean ± SD.
a 137.9 ng/mL is the median value of IGFBP-2 levels.
b Log-transformed variables.instructions. The detection limit was 0.2 ng/mL; the interassay
coefﬁcient of variability was 8.7%. Handling of samples and re-
agents as well as signal quantiﬁcation steps were all automated
(Biomek 2000, Beckman Coulter, Brea, CA, USA).2.9. Statistical analysis and data distribution
Data are presented as mean ± SD in tables and as mean ± SEM in
ﬁgures. Variables that were not normally distributed were log-
transformed as indicated in Tables. Subjects were divided accord-
ing to their IGFBP-2 circulating levels using a threshold corre-
sponding to the median (low IGFBP-2 < 137.9 ng/mL; high IGFBP-
2  137.9 ng/mL). Differences in clinical characteristics between
men with low and high IGFBP-2 levels were assessed using un-
paired t-tests. Men were also divided in 6 quantiles according to
their IGFBP-2 levels (Q1: <93.5; Q2: 93.6e113.2; Q3: 113.5e137.5;BP-2 <137.9 ng/mLa High IGFBP-2 137.9 ng/mL p value
± 8.2 45.6 ± 11.0 NS
± 11.9 84.6 ± 14.5 <0.0001
± 3.2 27.6 ± 4.24 <0.0001
± 8.8 97.7 ± 13.4 <0.0001
± 7.1 22.0 ± 9.45 <0.0001
± 71.2 170.5 ± 84.1 <0.0001
± 98.9 243.3 ± 109.4 <0.0001
± 0.47 5.68 ± 0.51 0.0006
± 221 1277 ± 248 <0.0001
± 74.4 89.7 ± 56.5 <0.0001
± 116828 95,775 ± 65576 <0.0001
± 2.90 3.21 ± 2.15 <0.0001
± 13.2 20.4 ± 11.7 <0.0001
± 6.97 10.2 ± 9.0 0.0007
± 1.82 2.08 ± 2.16 0.05
± 0.82 1.41 ± 1.13 NS
± 2.85 8.47 ± 6.55 <0.0001
± 0.44 1.48 ± 2.22 0.07
e e
± 1.15 1.8 4 ± 0.88 <0.0001
± 0.80 4.91 ± 0.85 0.0004
± 1.18 5.11 ± 1.32 <0.0001
± 0.19 1.03 ± 0.22 <0.0001
± 0.14 1.17 ± 0.17 NS
± 0.06 0.14 ± 0.06 <0.0001
± 1.05 1.36 ± 0.81 <0.0001
± 0.56 0.74 ± 0.43 <0.0001
± 0.18 0.88 ± 0.20 0.003
± 0.12 0.26 ± 0.10 <0.0001
± 0.74 3.16 ± 0.77 NS
± 0.54 0.96 ± 0.48 0.09
± 0.27 0.63 ± 0.28 0.10
± 0.66 1.65 ± 0.57 NS
± 14.2 29.2 ± 13.0 0.13
± 6.3 19.1 ± 6.3 0.10
± 18.3 51.7 ± 17.2 0.08
± 4.4 252.8 ± 4.6 0.09
± 0.06 0.21 ± 0.05 <0.0001
± 0.18 1.0 1 ± 0.24 0.001
± 2.26 82.4 ± 2.25 0.01
curve, HDL: High-density lipoprotein, HOMA-IR: Homeostasis model assessment of
oprotein, TNF: Tumor necrosis factor, VLDL: Very-low density lipoprotein. Values are
Fig. 1. Excursion of plasma glucose (A) and insulin (B) during an OGTT and in
asymptomatic men according to their quantiles of IGFBP-2 levels. C. Fat mass. Columns
with different letters represent groups that are statistically different from each
another. Q1: <93.5; Q2: 93.6e113.2; Q3: 113.5e137.5; Q4: 137.9e169.9; Q5:
170.2e221.4 and Q6: >221.5 ng/mL.
S. Carter et al. / Atherosclerosis 237 (2014) 645e651648Q4: 137.9e169.9; Q5: 170.2e221.4 and Q6: >221.5 ng/mL) in order
to compare the different groups on the basis of their response to
OGTT and with the criteria for the clinical diagnosis of the meta-
bolic syndrome as proposed by the NCEP ATP III [35].
Linear regression analyses were performed to identify the
metabolic correlates of IGFBP-2, VLDL-TG and HDL-C. Multivariate
stepwise regression analyses were performed to quantify the in-
dependent contributions of age, waist circumference, AUC insulin,
ALT and IGFBP-2 to the variance in VLDL-TG or HDL-C. A p value
<0.05 was considered signiﬁcant. All statistical analyses were per-
formed using the SAS statistical system (version 9.3; SAS Institute,
Cary, NC).
3. Results
3.1. Clinical data
The anthropometric and metabolic characteristics of the 379
volunteers are presented in Table 1. Subjects showed moderate
abdominal obesity (103.3 ± 12.6 cm), elevated TG
(2.21 ± 1.09 mmol/L), and low HDL-C (0.97 ± 0.21 mmol/L) con-
centrations. When men were dichotomized according to their
IGFBP-2 levels using themedian value, subjects with lower levels of
IGFBP-2 were characterized by higher weight, fat mass and visceral
and subcutaneous adipose tissue accumulation (p < 0.0001 for all).
These individuals also showed decreased insulin sensitivity as
assessed by higher fasting insulin (p < 0.0001), fasting glucose
(p ¼ 0.0006), AUC insulin (p < 0.0001), AUC glucose (p < 0.0001)
and HOMA-IR index (p < 0.0001; Table 1).
Men with higher IGFBP-2 levels also displayed lower VLDL-C
(p < 0.0001) concentrations as well as lower total cholesterol/
HDL-C ratio (p < 0.0001). These subjects also exhibited lower to-
tal TG (p < 0.0001). This difference was reﬂected by lower TG levels
in VLDL, LDL and HDL fractions (p < 0.0001 for all). Menwith higher
IGFBP-2 concentrations also had lower apo B (p < 0.0001) and total
cholesterol (p ¼ 0.0004) levels. These individuals were also char-
acterized by higher HDL-C concentrations and HDL particle size
(p ¼ 0.0010; p ¼ 0.01, respectively) when compared to men in the
low IGFBP-2 group.
To further examine the relationship of circulating IGFBP-2 to the
metabolic proﬁle, the cohort was separated into 6 quantiles ac-
cording to their IGFBP-2 levels. Importantly, levels of IGFBP-2 were
incrementally associated with the glucose and insulin response
curves during an OGTT and, as expected with total fat mass (Fig. 1).
Such analysis revealed progressive changes in insulinemia
(p < 0.0001), fat mass (p < 0.0001), waist circumference
(p < 0.0001), as well as in fasting glucose (p < 0.0001), plasma TG
(p < 0.0001), and HDL-C (p ¼ 0.0002) levels according to IGFBP-2
concentrations. Only the individuals in the 6th quantile
(>221.5 ng/mL) of IGFBP-2 levels did not meet the criteria for the
diagnosis of the metabolic syndrome whereas the 5th quantile
(170.2e221.4 ng/mL) regrouped individuals whowere at the cut-off
value for most criteria (i.e. waist circumference: 98.3 ± 12.7 cm;
fasting glucose: 5.68 ± 0.44 mmol/L; HDL-C: 0.99 ± 0.27 mmol/L)
(Fig. 2).
3.2. Associations between circulating IGFBP-2 and lipoprotein/lipid
variables
We ﬁrst examined the univariate associations between circu-
lating IGFBP-2 levels and the plasma lipoprotein-lipid proﬁle
(Table 2). Variables showing the strongest correlation with circu-
lating IGFBP-2 levels were VLDL-, LDL- and HDL-TG (all r ¼ 0.51,
p < 0.0001) levels, and VLDL-C (r ¼ 0.44, p < 0.0001) concentra-
tions. IGFBP-2 circulating levels were also signiﬁcantly associatedwith total apo B concentrations (r ¼ 0.30, p < 0.0001), as well as
with VLDL-apo B levels (r ¼ 0.33, p < 0.0001).
In addition to IGFBP-2, the other signiﬁcant correlates of VLDL-
TG concentrations were age (r ¼ 0.21, p < 0.0001), waist circum-
ference (r ¼ 0.54, p < 0.0001), insulin resistance as represented by
the AUC (r ¼ 0.50, p < 0.0001), and ALT (r ¼ 0.22, p < 0.0001);
Table 3a. Multivariate analyses revealed that after adjustment for
these variables, circulating IGFBP-2 levels (p < 0.0001) remained
independently associated with VLDL-TG levels (partial R2: 0.07,
p < 0.0001) (Table 3a).
Circulating levels of HDL-C were also related to IGFBP-2 con-
centrations (r¼ 0.27, p< 0.0001; Table 2). Other correlates of HDL-C
(Table 3b) included waist circumference (r ¼ 0.38, p < 0.0001),
insulin resistance as represented by the AUC (r ¼ 0.22,
p < 0.0001), and ALT (r ¼ 0.34, p < 0.0001). After adjustment for
Fig. 2. Levels of cardiometabolic risk variables across subgroups of subjects classiﬁed on the basis of their quantiles of IGFBP-2 concentrations. Dotted lines represent cut-off values
for the clinical identiﬁcation of the metabolic syndrome according to the NCEP ATP III panel (waist circumference: 102 cm; plasma TG: 1.69 mmol/L; HDL-C: 1.03 mmol/L; fasting
glucose: 5.6 mmol/L). Columns with different letters represent groups that are statistically different from each another. IGFBP-2 quantiles as in Fig. 1.
S. Carter et al. / Atherosclerosis 237 (2014) 645e651 649these variables, circulating IGFBP-2 levels were no longer inde-
pendently associated with HDL-C levels (Table 3b).
4. Discussion
The present study shows that men with lower circulating levels
of IGFBP-2 had a deteriorated lipoprotein-lipid proﬁle and that
plasma IGFBP-2 is independently associated with VLDL TG but not
with HDL-C levels in a cohort of asymptomatic men with various
degrees of adiposity. Based on the clinical criteria used for the
diagnosis of the metabolic syndrome proposed by the NCEP ATP III
[35], and within the limits of the present study, our data also
suggest that men with circulating levels of IGFBP-2 < 221.5 ng/mL
are at a higher risk of developing metabolic dysregulations asso-
ciated with the metabolic syndrome.
As expected [12], when dichotomizing subjects according to the
median (137.9 ng/mL), men in the low IGFBP-2 group showed
increased body fat mass, abdominal obesity and impaired glucose
tolerance. These observations are consistent with previous reports
showing strong associations between circulating IGFBP-2, indices of
adiposity and insulin sensitivity [16,18]. However, by dividing our
cohort into 6 quantiles, wewere able to establish a fairly continuous
relationship between IGFBP-2 and plasma glucose-insulin homeo-
stasis, men with low IGFBP-2 having to secrete higher levels of in-
sulin to maintain their glycemia than subjects with higher IGFBP-2
levels. Circulating IGFBP-2 levels in our cohort (158.2 ± 79.4 ng/mL)
were in the range of previous reports characterizing menwith mild
dyslipidemia and increased adiposity [13,16,37].
Men with low IGFBP-2 levels were characterized by an altered
lipoprotein/lipid proﬁle when compared to subjects in the high
IGFBP-2 group. Notably, individuals in the low IGFBP-2 groupdisplayed an increased number of VLDL particles, elevated plasma
TG as reﬂected by elevated TG in all lipoprotein subfractions, lower
HDL-C and smaller HDL particles. These ﬁndings are consistent
with and extend reports of negative associations between circu-
lating levels of IGFBP-2 and plasma TG and HDL-C concentrations
[17,21].
Since men in the high IGFBP-2 group also showed mild signs of
dyslipidemia, increased waist circumference and high fasting gly-
cemia, subjects were further divided into 6 quantiles to test
whether a metabolically healthy group of subjects could be iso-
lated. This classiﬁcation into several subgroups allowed us to
identify a subgroup of men with normal lipid proﬁles, waist
circumference and fasting glycemia. These individuals were found
in the highest IGFBP-2 level subgroup (6th group; IGFBP-2
levels > 221.5 ng/mL) and were the only one not meeting the
criteria for the clinical diagnostic of the metabolic syndrome pro-
posed by the NCEP ATP III. This suggests that a decrease in IGFBP-2
levels is incrementally associated with deterioration in metabolic
risk factors. Whether IGFBP-2 levels are predictive of the devel-
opment of the metabolic syndrome is an issue that remains to be
examined in longitudinal studies but our data suggest the utiliza-
tion of IGFBP-2 as an integrative biomarker for metabolic
syndrome.
The concomitant occurrence of abnormalities in all major lipo-
protein fractions observed in participants with low levels of IGFBP-
2 can be explained by their metabolic relationships. Over-
production of apo B-containing VLDL particles is a common alter-
ation associated with hepatic insulin resistance [38]. Consequently,
in the liver of these patients, TG synthesis and storage are
increased, and excess TG is secreted as VLDL. Altered catabolism is
also a hallmark of diabetic dyslipidemia, partly due to decreased
Table 2
Relationships between IGFBP-2 and features of the lipoprotein-
lipid proﬁle.
IGFBP-2a
VLDL cholesterola r ¼ 0.44**
n ¼ 375
HDL cholesterola r ¼ 0.27**
n ¼ 375
VLDL triglyceridesa r ¼ 0.51**
n ¼ 375
LDL triglyceridesa r ¼ 0.51**
n ¼ 375
HDL triglyceridesa r ¼ 0.51**
n ¼ 375
Apo A1 r ¼ 0.10
n ¼ 375
Apo B r ¼ 0.30**
n ¼ 375
VLDL apo B r ¼ 0.33**
n ¼ 375
LDL apo B r ¼ 0.22**
n ¼ 375
Large LDL r ¼ 0.16*
n ¼ 184
Medium LDL r ¼ 0.17*
n ¼ 184
Small LDL r ¼ 0.10
n ¼ 184
% Large LDL r ¼ 0.13
n ¼ 186
% Medium LDL r ¼ 0.16*
n ¼ 186
% Small LDL r ¼ 0.16*
n ¼ 186
LDL size r ¼ 0.10
n ¼ 282
HDL size r ¼ 0.17*
n ¼ 238
*p < 0.05; **p < 0.0001.
a Log-transformed variable.
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residence time in the vasculature and enriching LDL and HDL par-
ticles with TG. In this study, hepatic insulin resistance was not
evaluated but surrogate markers of insulin resistance were
measured (fasting glucose and insulin, HOMA, AUC insulin) and
subjects with low IGFBP-2 levels showed characteristics related to
insulin resistance. Whether low IGFBP-2 levels are associated with
increased secretion of apo-B containing particles or decreased
clearance remains to be tested using kinetic in vivo studies.Table 3
A: Correlates of VLDL triglycerides. B: Correlates of HDL cholesterol.
Univariate Multivariate model
r p value Partial R2 Model R2 p value
A
Age 0.21 <0.0001 0.03 0.03 0.0001
Waist circumference 0.54 <0.0001 0.29 0.32 <0.0001
AUC insulina 0.50 <0.0001 0.01 0.33 0.02
ALTa 0.22 <0.0001 e 0.33 NS
IGFBP-2a ¡0.51 <0.0001 0.07 0.40 <0.0001
B
Age 0.06 0.28 e e NS
Waist circumference 0.38 <0.0001 0.15 0.15 <0.0001
AUC insulina 0.22 <0.0001 0.01 0.16 0.02
ALTa 0.34 <0.0001 e 0.16 NS
IGFBP-2a 0.25 <0.0001 e 0.16 NS
ALT: Alanine aminotransferase, AUC: Area under the curve, IGFBP: Insulin-like
growth factor binding protein. The multivariate model is adjusted for variables
that were signiﬁcantly associated with the variable of interest in univariate analysis
as well as other clinically relevant variables (i.e. age) regardless of their statistical
signiﬁcance.
a Log-transformed variables.Considering the established interactions between IGFBP-2
levels, hyperinsulinemia and markers of adiposity, we wanted to
quantify the speciﬁc contribution of IGFBP-2 to the variance of
circulating lipids and lipoproteins. Our results indicate that after
adjustments for concomitant variables, IGFBP-2 remained inde-
pendently associated with VLDL-TG levels. When similar analyses
were conducted for HDL-C, IGFBP-2 did not remain independently
associated with this variable. This observation contrasts with a
recent study showing that IGFBP-2 levels can predict longitudinal
changes in HDL-C over an 8-year period in a populationwith type 2
diabetes [21]. This discordance might be attributable to the cross-
sectional nature of the present study and to the different pop-
ulations examined.
The hardly dissociable relationship between IGFBP-2 and insulin
sensitivity could partly explain the observed association between
plasma IGFBP-2 and VLDL-TG levels; however, our results are
consistent with actions of IGFBP-2 beyond insulin sensitivity. There
is currently no report of direct interactions between plasma IGFBP-
2 and VLDL production/secretion; IGFBP-2 is, however, implicated
in various molecular pathways that could inﬂuence hepatic secre-
tion of VLDL. IGFBP-2 modulates phosphatase and tensin homolog
(PTEN), which could in turn inﬂuence hepatic apo B production and
secretion [40]. Whether IGFBP-2 impacts the lipid proﬁle through
direct actions on extrahepatic lipoprotein metabolism remains to
be explored.
4.1. Clinical implications
The present study supports the notion that the metabolic al-
terations associated with increased circulating VLDL are also
associated with low circulating IGFBP-2 levels. We therefore sug-
gest that low circulating IGFBP-2 levels could be an early marker of
dyslipidemia, although this hypothesis remains to be experimen-
tally veriﬁed. Whether these low levels are a cause or a conse-
quence of increased plasma VLDL still needs to be conﬁrmed.
Accordingly, we identiﬁed a subpopulation of men (IGFBP-2
levels < 221.5 ng/mL) who met the clinical criteria proposed by the
NCEP ATP III for the diagnosis of the metabolic syndrome [35]. It is
important to point out that these asymptomatic male subjects were
not under any medication but, according to current guidelines,
could be good candidates for lipid and glucose lowering therapy or
for a lifestyle modiﬁcation intervention, further supporting the
potential use of IGFBP-2 as an early, complementary biomarker for
metabolic syndrome. Additional longitudinal studies will be
required to delineate the relative contribution of IGFBP-2 to the
development of alterations in lipid metabolism and to validate the
cut-off value suggested herein.
4.2. Limitations of the study
The design of this study was cross-sectional and our observa-
tions do not imply causality. Considering the fact that participants
were recruited through the media, there is obviously a recruitment
bias. Furthermore, all participants were Caucasian males between
20 and 65 years old. Therefore, our results need to be validated in
other cohorts. Nonetheless, the present hypothesis-generating
study should entail further investigations involving different pop-
ulations and validation of IGFBP-2 as a biomarker of early
dyslipidemia.
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